mRNA vaccine for the novel coronavirus variant strain(Omicron JN.1)
新型冠状病毒变异株mRNA疫苗（Omicron JN.1）
Report date: 2025/10/23 20:00:06
Base Information
Drug NamemRNA vaccine for the novel coronavirus variant strain(Omicron JN.1)
Drug Alias Name
Classification +[4]
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWalvax Biotechnology Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesShanghai Rnacure Biopharma Co LtdWalvax Biotechnology Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A